Across TCGA pan-cancer cohorts, SNORD3C Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SNORD3C data layer compared with 12 for mass-spec protein.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher SNORD3C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNORD3C expression acts as an unfavorable survival marker.
CHOL are the cancer types where SNORD3C Mutation most reproducibly stratifies survival.